← Leaderboards
Cullen Mitsuo Taniguchi
University Of Tx Md Anderson Can Ctr
$3,293,212
Attributed
$3,386,834
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2019–24$2.5M$1.9M$1.3M$625K$0
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$6,655,519 · 5
By mechanism
U54$4,005,020 · 3
R01$2,650,499 · 2
Top collaborators
- Sharon Hermes Giordano5 shared
- Elizabeth L Travis5 shared
- Brad R Weiner5 shared
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Ruy Lopez Ridaura$1,748,418
- Guillermo Tortolero-Luna$6,522,932
- Albert Koong$7,304,561
- Carolina Jannet Garcia Garcia$99,042
- Cesaltina Ferreira Lorenzoni$1,475,824
Others in their field
Other Emerging Leaders on “Grant”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$208,271,537
- Kimberly Smith · Ppd Development Lp$115,671,664
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$76,895,673
- Julie Brisset · The University Of Central Florida Board Of Trustees$41,275,036
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
Research focus
GrantInstitutionLaboratoriesMalignant Neoplasm Of PancreasDiagnosisTumorSignal TransductionInnovationPancreatic NeoplasmClinical TrialsPharmaceutical PreparationsIntestinesMalignant NeoplasmsUnresectableRadiation ProtectionHypoxiaPancreasEvaluationPancreatic Cancer PatientsMolecularOxygenTranslatingBiologyClinically Relevant
Grant awards (18)
The Role of HIF2 in Pancreatic Ductal Adenocarcinoma$65,685
R01 · FY2024 · CA · contact PI
The Role of HIF2 in Pancreatic Ductal Adenocarcinoma$572,667
R01 · FY2023 · CA · contact PI
The Role of HIF2 in Pancreatic Ductal Adenocarcinoma$37,001
R01 · FY2023 · CA · contact PI
UPR/MDACC: Partnership for Excellence in Cancer Research (1 of 2)$1,091,199
U54 · FY2022 · CA
Planning and Evaluation Core (PEC)$543,047
U54 · FY2022 · CA · contact PI
Translating Intestinal Radioprotection by EGLN Inhibition to Improve Clinical Outcomes in Unresectable Pancreatic Cancer$370,985
R01 · FY2022 · CA · contact PI
Project-001$124,829
U54 · FY2022 · CA
Translating Intestinal Radioprotection by EGLN Inhibition to Improve Clinical Outcomes in Unresectable Pancreatic Cancer$118,163
R01 · FY2022 · CA · contact PI
Translating Intestinal Radioprotection by EGLN Inhibition to Improve Clinical Outcomes in Unresectable Pancreatic Cancer$67,758
R01 · FY2022 · CA · contact PI
UPR/MDACC: Partnership for Excellence in Cancer Research (1 of 2)$1,054,072
U54 · FY2021 · CA
Translating Intestinal Radioprotection by EGLN Inhibition to Improve Clinical Outcomes in Unresectable Pancreatic Cancer$499,128
R01 · FY2021 · CA · contact PI
UPR/MDACC: Partnership for Excellence in Cancer Research (1 of 2)$77,754
U54 · FY2021 · CA
Translating Intestinal Radioprotection by EGLN Inhibition to Improve Clinical Outcomes in Unresectable Pancreatic Cancer$69,142
R01 · FY2021 · CA · contact PI
Planning and Evaluation Core (PEC)$68,459
U54 · FY2021 · CA · contact PI
UPR/MDACC: Partnership for Excellence in Cancer Research (1 of 2)$1,045,660
U54 · FY2020 · CA
Translating Intestinal Radioprotection by EGLN Inhibition to Improve Clinical Outcomes in Unresectable Pancreatic Cancer$378,555
R01 · FY2020 · CA · contact PI
Translating Intestinal Radioprotection by EGLN Inhibition to Improve Clinical Outcomes in Unresectable Pancreatic Cancer$92,860
R01 · FY2020 · CA · contact PI
Translating Intestinal Radioprotection by EGLN Inhibition to Improve Clinical Outcomes in Unresectable Pancreatic Cancer$378,555
R01 · FY2019 · CA · contact PI